NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
58.21
+0.48 (+0.83%)
The current stock price of INCY is 58.21 USD. In the past month the price decreased by -3.91%. In the past year, price increased by 11.19%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2617
Company Website: https://www.incyte.com/
Investor Relations: https://investor.incyte.com/
Phone: 13024986700
The current stock price of INCY is 58.21 USD. The price increased by 0.83% in the last trading session.
The exchange symbol of INCYTE CORP is INCY and it is listed on the Nasdaq exchange.
INCY stock is listed on the Nasdaq exchange.
33 analysts have analysed INCY and the average price target is 76.76 USD. This implies a price increase of 31.87% is expected in the next year compared to the current price of 58.21. Check the INCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INCYTE CORP (INCY) has a market capitalization of 11.26B USD. This makes INCY a Large Cap stock.
INCYTE CORP (INCY) currently has 2617 employees.
INCYTE CORP (INCY) has a support level at 57.64 and a resistance level at 62.47. Check the full technical report for a detailed analysis of INCY support and resistance levels.
The Revenue of INCYTE CORP (INCY) is expected to grow by 10.96% in the next year. Check the estimates tab for more information on the INCY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INCY does not pay a dividend.
INCYTE CORP (INCY) will report earnings on 2025-04-29, before the market open.
The PE ratio for INCYTE CORP (INCY) is 44.1. This is based on the reported non-GAAP earnings per share of 1.32 and the current share price of 58.21 USD. Check the full fundamental report for a full analysis of the valuation metrics for INCY.
The outstanding short interest for INCYTE CORP (INCY) is 3.09% of its float. Check the ownership tab for more information on the INCY short interest.
ChartMill assigns a technical rating of 1 / 10 to INCY. When comparing the yearly performance of all stocks, INCY turns out to be only a medium performer in the overall market: it outperformed 50.32% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to INCY. While INCY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 1.32. The EPS decreased by -62.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 0.77% | ||
ROA | 0.6% | ||
ROE | 0.95% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 74% to INCY. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 350.35% and a revenue growth 10.96% for INCY